PODCAST · business
The Health Pod
by Baker McKenzie
The Health Pod is Baker McKenzie's industry podcast series which highlights sector specific issues and trends that affect healthcare and life sciences companies.
Episodes
-
Episode 14: Japan Medical Device Market –Distinguishing Features and Industry Practice
Japan's global strength in the medical device sector, aging population and wealth of know-how and technology make it a fascinating medical device discovery and development market. In the second installment of our Spotlight on Japan mini-series, Chris Hodgens, Ryosuke Tateishi and Wabi Tanaka —...
-
Episode 13: Japan Medical Device Market – Healthcare Apps and Software as a Medical Device (SaMD)
We frequently receive regulatory questions about the increasing number and variety of healthcare apps being developed in Japan and elsewhere in the world. From a regulatory point of view, the most important issue is whether a particular app will be treated as a regulated medical device under the...
-
Episode 12: Japan Pharmaceuticals Market – Compliance
Compliance is one of the key factors for pharmaceutical companies in running a sustainable business in Japan. In our fourth installment of the Spotlight on Japan mini-series, industry specialists Ryosuke Tateishi, Mami Ohara and Rie Kuwabara, Healthcare & Life Sciences Compliance and Regulatory...
-
Episode 11: Virtual Power Purchase Agreements
Corporate virtual power purchase agreements (vPPAs) have become increasingly popular and sophisticated products as a means of achieving sustainability-related goals. In this episode, Clyde (Skip) Rankin joins David Wardell to explain what vPPAs are, how they work, and their benefits for our...
-
Episode 10: Hyper-Hybridity: Defining a New Era of Digital Health Innovation
Digital healthcare plays a pivotal role in the future of patient care: the pandemic has accelerated digital health reforms and provided a plethora of opportunities for healthcare and life sciences, technology and financial companies. In Asia Pacific, in particular, a rapidly expanding population,...
-
Episode 9: Japan Pharmaceuticals Market – Drug Development
With a strong pharmaceutical sector, an ageing population and a wealth of expertise, Japan is a fascinating drug discovery and development market. In our third installment of the Spotlight on Japan mini-series, Chris Hodgens, Real Estate Practice Group partner and industry specialist, Ryosuke...
-
Episode 8: Surviving and Thriving in the New Normal
As businesses resume operations and plan ahead to the post-pandemic world, in this episode of The Health Pod, Barry Thompson speaks to David Wardell about his perspective and insights on the importance of anticipating the potential litigation consequences of the pandemic, focusing on force…
more -
Episode 7: The Ins and Outs of Handling Material Non-Public Information
Healthcare and life sciences are among the most heavily regulated industries and the US Securities and Exchange Commission continues to focus on healthcare and life sciences companies when it comes to disclosure and reporting requirements. If not managed carefully, the treatment and misuse of...
-
Episode 6: Japan Pharmaceuticals Market – Regulatory Landscape
With global pharma experiencing increasing levels of reorganization and M&A activity, our second installment of the Spotlight on Japan mini-series, with Mihoko Ida, a corporate partner based in Baker McKenzie's Tokyo office and Mami Ohara, a member of the Healthcare & Life Sciences Group with...
-
Episode 5: Japan Pharmaceuticals Market – Distinguishing Features and Industry Practice
Japan accounts for approximately 7% of the global pharmaceuticals market and is the third largest market in the world following the US and China. In the first installment of the Spotlight on Japan mini-series, Hideo Norikoshi, head of the Tokyo office's Healthcare & Life Sciences industry group…
more -
Episode 4: UK and EU Competition Law in times of COVID-19 and beyond
The COVID-19 crisis has required competition authorities to adjust their enforcement priorities and seen a temporary relaxation of certain competition laws in response to the pandemic. In this episode of The Health Pod, Irena Apostopoulos joins Dave Wardell to discuss the impact of the pandemic…
more -
Episode 3: Alternative Funding Arrangements in Biopharma Clinical Development
The lengthy, expensive and complex nature of drug development has brought about the emergence of alternative funding entities to help boost R&D productivity, lower costs and mitigate risks. In this episode, Randall Sunberg joins David Wardell in discussing how these investment companies are...
-
Episode 2: COVID-19 Impact on Biopharma Clinical Development in the EU and Mexico
The disruptive impact of COVID-19 has forced the healthcare and life sciences industries to adapt in different ways. In this episode of The Health Pod, Els Janssens and Christian Lopez-Silva, join Dave Wardell in discussing the effect COVID-19 has had on the management of clinical trials in the…
more -
Episode 1: Health Canada and the FDA’s response to COVID-19
Resolving the health crisis demands an immediate response from regulatory agencies. In this episode, Kamleh Nicola and Veleka Peeples-Dyer join Dave Wardell in discussing some of the most significant responses by Health Canada and the FDA to COVID-19.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
Loading similar podcasts...